Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Long-term cohort studies

Topic: Risk, prevention and care in population studies

Agents currently in use against human immunodeficiency virus (HIV) infection, including the prospects of a vaccine, have focused primarily on destroying or disabling the virus. This strategy is hampered by the ephemeral nature of the viral genome. Lithium salts are widely used in psychiatry as mood-stabilizing agents. Studies have revealed, however, that the lithium ion also has significant granulopoietic actions, as well as regulatory effects on select cytokines that enable it to boost the body's natural defense against viral infections, specifically DNA viruses. Moreover, case reports in acquired immunodeficiency syndrome (AIDS) patients, as well as animal studies using related immunodeficiency viruses, provide support for a novel therapeutic role for lithium salts in the treatment of HIV infection. Furthermore, recent studies have revealed an important additional benefit of the lithium ion. In both in vitro and human studies, lithium has been found to increase the synthesis of neuroprotective proteins and to exert possible neurotrophic effects in the human brain. These properties hold great promise in the treatment of AIDS-related neurological deficits such as dementia. This paper reviews the mechanisms involved in and the clinical promise for lithium salts in the treatment of AIDS and AIDS-related dementia.

Key findings

Why it matters

This review paper discusses mechanisms by which lithium salts might boost defence against viral infections and increase neuroprotective proteins, with possible relevance to AIDS-related dementia. It is a review of mechanisms and case reports, not a trial, so it does not establish that lithium treats or prevents dementia.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 26 of the 96 points it could be judged on, which is 27 of 100. Total 27 of 100.26 of the 96 points we could judge = 27 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Psychopharmacology Bulletin)
Journal's citation record 0 / 4 Psychopharmacology Bulletin: journal h-index 54 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2002 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 30 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.2 citations a year over 26 year(s) since 2002
Impact for its field and year 1 / 6 Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 0 / 3 North-West University: institution h-index 360 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 12397845)
Free to read 0 / 2 Behind a paywall — scores zero
Points 26 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100.
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Harvey, B. H., Meyer, C. L., Manji, H. K., Gallicchio, V. S., Frcpc, et al. (2002). Lithium Salts in AIDS and AIDS-Related Dementia. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4228

Vancouver

Harvey BH, Meyer CL, Manji HK, Gallicchio VS, Frcpc, et al. Lithium Salts in AIDS and AIDS-Related Dementia. Psychopharmacology Bulletin. 2002. doi:10.64719/pb.4228. PMID: 12397845.

BibTeX

@article{harvey2002-12397845,
  author  = {Harvey, Brian Herbert and Meyer, Catharina L. and Manji, Husseini K. and Gallicchio, Vincent S. and Frcpc and others},
  title   = {{Lithium Salts in AIDS and AIDS-Related Dementia}},
  journal = {Psychopharmacology Bulletin},
  year    = {2002},
  doi     = {10.64719/pb.4228},
  pmid    = {12397845},
  url     = {https://doi.org/10.64719/pb.4228}
}

Related studies in Long-term cohort studies

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →